Source comparison
DSIP vs Sermorelin: Research Peptide Comparison
Primary Mechanism Modulates hypothalamic neuronal excitability and ion channel activity to increase delta wave sleep Binds GHRH receptors in anterior pituitary, triggering endogenous growth hormone release Entirely distinct biological targets. DSIP acts on CNS
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Modulates hypothalamic neuronal excitability and ion channel activity to increase delta wave sleep
- Binds GHRH receptors in anterior pituitary, triggering endogenous growth hormone release
- Entirely distinct biological targets. DSIP acts on CNS sleep architecture; Sermorelin acts on endocrine GH secretion
- Half-Life
- 15–30 minutes in plasma
- 8–12 minutes in plasma
- Both are short-acting, requiring timing around intended effect window (sleep onset for DSIP, evening for Sermorelin)
- Dosing Range (Research)
- 25–250 mcg subcutaneously or intranasally, 30–90 minutes before sleep
- 100–500 mcg subcutaneously once daily, typically evening
- DSIP requires pre-sleep timing; Sermorelin aligns with nocturnal GH rhythm but doesn't require immediate sleep onset
- Measurable Endpoints
- Polysomnography metrics: slow-wave sleep %, sleep latency, delta power density
- Serum IGF-1, fasting GH levels, body composition (DEXA), lean mass changes
- DSIP outcomes are neurophysiological; Sermorelin outcomes are metabolic/anabolic. Fundamentally different study designs
- Evidence Base Strength
- Limited modern RCTs; primary evidence from 1970s–1980s Eastern European research
- Moderate-to-strong evidence base with multiple Phase II/III trials in GH deficiency populations
- Sermorelin has substantially more robust contemporary clinical validation than DSIP
- Suitability for Sleep Studies
- Directly modulates sleep architecture. Appropriate for circadian rhythm, insomnia, or sleep quality research
- No direct sleep-modulating mechanism; may indirectly improve subjective sleep quality via metabolic effects
- DSIP is the correct choice for sleep architecture studies; Sermorelin is inappropriate for that endpoint